Skip to content

An Immersive Virtual Reality-Based Early Neurocognitive Stimulation System (VR-ENSS) for Critically Ill Neurological Patients: Development and Usability Testing Analysis

Development and Implementation of an Immersive Virtual Reality-Based Early Neurocognitive Stimulation System for Critically Ill Patients in the ICU

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096265
Enrollment
Unknown
Registered
2025-01-21
Start date
2025-02-08
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium

Interventions

Pilot intervention group.:Assist the patient in adopting a comfortable position before each session, elevate the head of the bed by 30°, and instruct the patient on the use of the VR equipment. To avo

Sponsors

Beijing Tiantan Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with neurological diseases. 2. Age >= 18 years old; 3. ICU stay duration = 13 (for patients with tracheal intubation, >= 9); 5. Richmond Agitation Sedation Scale (RASS) score ranging from -1 to 1; 6. Muscle strength of at least one upper limb >= Grade IV; normal cognitive and comprehension abilities; 7. Informed consent, willing to participate and cooperate in this study.

Exclusion criteria

Exclusion criteria: 1. Patients with severe visual or hearing impairments that make it difficult to cooperate with VR training; 2. Patients who are unable to use VR equipment due to active contraindications (such as limited head and neck movement, unstable fractures), balance disorders, etc.; 3. Patients who are unable to understand VR video or game instructions and cannot follow simple commands; 4. Patients with delirium or confusion; 5. Patients with infectious diseases or under contact isolation; 6. Patients suspected or confirmed of drug abuse, alcoholism/excessive use, or withdrawal symptoms; 7. Patients participating in other studies.

Design outcomes

Primary

MeasureTime frame
Feasibility;Safety;Acceptance;

Countries

China

Contacts

Public ContactWeixin Cai

Beijing Tiantan Hospital Affiliated to Capital Medical University

ttyyhlb@163.com+86 139 0105 4339

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026